Searched for
GLENMARK STOCK PRICE
These large-caps have ‘strong buy’ & ‘buy’ recos and an upside potential of up to 27%As the market seems to be in comeback mode, it helps to be aware that the best (and probably biggest) wealth creator of the last couple of ...- These large- and mid-cap stocks can give more than 25% return in 1 year, according to analystsThere are market phases when one risk dominates. Then there are phases like this, when risks arrive from every direction and refuse to stan...
- Long-term Investing: Ecosystem with an edge called India; 12 large- mid- and small-cap stocks with upside potential of up to 34%Tactical investing should not be confused with long-term investing. In a world where geopolitical risk, commodity shocks, and uncertainty a...
- Mankind, other pharma stocks rally up to 7%; Nifty Pharma scales fresh peak. What lies ahead?Pharma stocks surged on Wednesday, supported by strong earnings and a weakening rupee, even as Sensex and Nifty traded lower. The Nifty Pha...
- Nifty finds support: Nagaraj Shetti spots 2 breakout stocks worth watchingNifty's Monday pullback is a technical dip, not a trend reversal, says HDFC Securities analyst Nagaraj Shetti. After forming a higher botto...
- US tariffs on metals and pharma: Which Indian stocks are safe and which aren't: Sudip BandyopadhyayIndian equity markets face policy risks from US tariffs and West Asia conflict. These issues impact metals and pharmaceutical sectors. Expe...
- Two Trades for Today: A pharma major for a 6% upmove, a mid-cap healthcare stock for a gain of about 5%Our technical analysts identify select stocks that may gain momentum even in volatile markets. Here are the technical calls for today.
- Stock Radar: Glenmark Pharma breaks out from a range to hit fresh record high in March 2026; what should investors do?Glenmark Pharma Ltd has broken out of a 7-month consolidation on weekly charts, reaching fresh record highs. Experts suggest short-term tra...
- I-Sec maintains Reduce call on Glenmark Pharma, raises target price to Rs 1,300ICICI Securities maintains a Reduce call on Glenmark Pharmaceuticals, revising the target price to Rs 1,300. The brokerage anticipates reve...
- Reduce Glenmark Pharmaceuticals, target price Rs 1,265: ICICI SecuritiesICICI Securities maintains a Reduce call on Glenmark Pharmaceuticals with a target price of Rs 1,265. The current market price is Rs 1365.9...
- Glenmark closes 3% lower post API arm sale dealAccording to analysts, the sale of Glenmark Life could impact the profitability of Glenmark Pharma in FY25 but lower interest payments coul...
- Glenmark Life zooms 9%, hits 52-week high after Q4 resultsGlenmark Life Science's Q4 profit jumped 48% YoY to Rs146 crore, while revenue from operations rose 21% YoY to Rs621 crore. Its EBITDA grew...
- Glenmark Pharmaceuticals rises 5% on launching first 3-drug FDC for type-2 diabetes in India“This FDC has been launched under the brand name Zita®-PioMet,” the company said in a BSE filing. “This offers patients with Type 2 diabete...
- Stock Radar: This pharma company sees breakout after 6-month consolidation; time to buy?Short-term traders can look to buy the stock now or on dips for a possible target of Rs 474 in the next 4-6 weeks, suggested experts
- Buy Glenmark Pharmaceuticals, target price Rs 440: ICICI DirectGlenmark Pharmaceuticals Ltd., incorporated in the year 1977, is a Mid Cap company (having a market cap of Rs 11089.21 Crore) operating in ...
- Interim data from study supports Favipiravir's safety, effectiveness: GlenmarkThe study, commenced in July 2020, aimed to evaluate safety and efficacy of favipiravir in mild to moderate COVID-19 patients.
- Sell Glenmark Pharmaceuticals., target Rs 826: Microsec CapitalSell Glenmark Pharmaceuticals Ltd. at a price target of Rs 826 and a stop loss at Rs 860
- Glenmark falls as CS downgrades stock to 'Neutral' ahead of Q1 numbersCredit Suisse believes that the pharma stock is already pricing in the best case scenario, which includes sustenance of profitability from ...
- Glenmark Pharmaceuticals gains 7% on Q2 results; brokerages maintain buyThe company had posted a net profit of Rs 56.58 crore for the quarter ended September 30, 2011, Glenmark Pharmaceuticals said in a statemen...
- Optimistic about Glenmark: Gaurang Shah, Geojit BNP Paribas Financial ServicesGaurang Shah, Asst VP, Geojit BNP Paribas Financial Services, in a chat with ET Now talks about Glenmark.
Load More
